Colorectal Cancer | Topics

 
Rachel Pearlman, MS, LGC, Discusses Fine Tuning Genetic/Germline Testing for CRC
March 30, 2022

In an interview with CancerNetwork® during National Colorectal Cancer Awareness Month, Rachel Pearlman, MS, LGC, highlights recent updates in genetic testing in colorectal cancer and where the field needs to head to provide individuals with better options.

Leading Gastrointestinal Cancer Experts Discuss Targeted Therapies and Landscape of Treatment
March 28, 2022

Tanios Bekaii-Saab, MD; Kristen Ciombor, MD, MSCI; and John Strickler, MD, detail key developments and needs in the gastrointestinal cancers landscape.

CYAD-101 CRC Trial Receives Clinical Hold Following Discussion With FDA
March 04, 2022

A clinical hold has been placed on the phase 1b CYAD-101-002 trial, examining pembrolizumab after treatment with CYAD-101 and folinic acid, fluorouracil, and oxaliplatin preconditioning in metastatic colorectal cancer.

Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A Review
February 16, 2022

This review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.

Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer
February 15, 2022

This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.

Trend Identified Favoring First-Line Trifluridine/Tipiracil Plus Bevacizumab in Metastatic CRC
February 10, 2022

Treatment with trifluridine/tipiracil plus bevacizumab trended towards favorability despite not demonstrating statistically significant superiority in patients with metastatic colorectal cancer.

Colorectal Cancer Screening Rates Low Among Breast and Prostate Cancer Survivors in Single Center Study
February 04, 2022

According to a study conducted at a single cancer center in Southern Maryland, patients who survived breast or prostate cancer were less likely to receive a colorectal cancer screening.

Adding Nivolumab to SOC Fails to Extend PFS in Metastatic CRC
January 23, 2022

The CheckMate 9X8 trial did not hit the primary end point of progression-free survival superiority with nivolumab plus standard of care vs standard of care alone in metastatic colorectal cancer.

ctDNA Assays Identify Resectable CRC Likely to Benefit Adjuvant Chemotherapy
January 23, 2022

The observational GALAXY study found that use of a ctDNA assay could help determine which patients with colorectal cancer stand to benefit the most by receipt of adjuvant chemotherapy.

Trastuzumab Deruxtecan Shows Encouraging Efficacy for HER2+ Metastatic Colorectal Cancer
January 23, 2022

Treatment with trastuzumab deruxtecan produced promising efficacy results for patients with HER2-positive metastatic colorectal cancer.